Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.30
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.20 (2.439%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 8.30
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Meatable Announces US$ 47 Million Financing

23 Mar 2021 15:00

RNS Number : 2282T
Agronomics Limited
23 March 2021
 

23 March 2021

 

Agronomics Limited

("Agronomics" or the "Company")

Investee Company Update: Meatable Announces US$ 47 Million Series A Financing

 

Agronomics, the leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat, is pleased to announce portfolio company Meatable B.V. "Meatable" has closed a US$ 47 million Series A funding round, with participation from new investors Section 32, Jeffrey Leiden and strategic investor DSM, as well as support from existing investors, BlueYard Capital, Humboldt and Taavet Hinrikus in addition to Agronomics.

As stated in the announcement dated 18th February 2021, Agronomics invested € 2 million in this Series A round, for 1,197 preferred shares. Agronomics holds 4,752 preferred shares in Meatable, representing an equity ownership on a fully diluted basis, of 5.70%. Subject to audit, Agronomics will now carry this position in its accounts at a book value of € 7.95 million, representing an unrealised gain on cost of € 2.95 million.

The full announcement is set out below with no material changes or adjustments:

Meatable Raises $47 Million Series A to Continue Scaling Trajectory and Expand Its Product Portfolio with Beef

Consortium of life sciences and food investors Section 32, DSM Venturing, Dr. Rick Klausner, Dr. Jeffrey Leiden and existing investors was formed to optimally support Meatable for its next phase of growth

AMSTERDAM, March 23rd - Meatable, the cultivated meat startup, has closed $47 million USD in its Series A funding round, bringing the company's total funding to $60 million. Meatable finalized its first showcase product in 2020 and aims to use the new funds to advance smallscale production at the Biotech Campus Delft and to diversify its product portfolio.

The consortium consists of Dr. Rick Klausner Section 32, Jeffrey Leiden, and DSM, and includes existing investors, such as BlueYard Capital, Agronomics, Humboldt, and Taavet Hinrikus, showing continued support. They recognize the positive impact cultivated meat will have on climate change, see the trillion-dollar potential of the cultivated meat marketplace, and are betting on Meatable to solve the industry's scalability and speed-to-market challenges with its patented opti-ox™ technology.

Dr. Rick Klausner, former director of the US National Cancer Institute and former Executive Director of Global Health at the Bill & Melinda Gates Foundation, sees great potential in Meatable and its technology.

"We are committed to joining Meatable in its mission to address the world's most pressing challenges. We see a smart start-up that has accomplished a lot in a short amount of time. They have a great team and game-changing technology that can address the challenges around the global food insecurity issues our planet is facing," said Klausner. "They have all the right ingredients to become the leading choice for sustainably and efficiently produced meat."

Meatable's proprietary technology enables it to use pluripotent cells to replicate the natural process of fat and muscle growth, in proportions that emulate traditional cuts of meat. The entire process takes only weeks, where it takes years to grow a live animal.

"To be able to meet the growing demand for meat worldwide, we need breakthrough solutions. Cultivated meat has the potential to continue to produce the product we love - meat - using a much more efficient production process. Having Rick Klausner, Jeffrey Leiden, Section 32 and DSM support us in realizing that potential is a huge step for Meatable," said Krijn de Nood, CEO and co-founder of Meatable. "We are honored to welcome a like-minded

group of investors who support us on our mission - to develop, accelerate and bring to life sustainable, healthy and environmentally sound technologies that can improve the human condition. With this funding we believe we are well on our way to bringing our first products to market to sustainably satisfy the world's appetite for natural meat."

Meatable aims to produce cultivated meat, for which no animals are slaughtered, fewer GHG emissions are released, and significantly less land and water are required. And, unlike plantbased alternatives, the end-product will provide the full experience of eating actual meat, with the same texture, taste, and nutritional benefits.

After successfully completing its first pork showcase product, Meatable is currently focused on the further development of cultivated pork and beef. Meatable's technology is adaptable to any cell-based species, including cows, pigs, sheep and fish, giving the company great opportunity for further product development.

###

About Meatable

Meatable is a Dutch cultivated meat company aiming to deliver, at scale, the new natural, cultivated meat that looks like, tastes like, and has the nutritional profile of traditional meat. Its proprietary opti-ox technology enables Meatable to produce the meat rapidly, sustainably, and without harming animals. Founded in 2018 by Krijn de Nood (CEO), Daan Luining (CTO) and Dr. Mark Kotter (principal inventor of opti-ox technology), Meatable has brought together a team of experts with unique knowledge in fields including molecular biology, chemistry, tissue engineering, bioprocess development and food science to create the new natural meat. Follow Meatable: LinkedIn, Facebook, Instagram, Twitter.

Media Contacts:

Hilary McCarthy (US) hilary@clearpointagency.com Phone: +1 774.364.1440

Anke van de Vliet (Europe) anke@weare49stories.com

Note to editors: Facts/figures and photos available upon request

 

 

 

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of 16 companies at the Seed to Series B stage in this rapidly advancing sector. It seeks to secure a 5-10% initial ownership in technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

 

 

About the Cultivated Meat Sector

Funding in the cultivated meat sector is growing rapidly with c US$ 170 million invested globally between 2016-2019 and over US$ 270 million raised in 2020 alone. Additional financings are anticipated as the capital requirements of these companies grows to build out and scale up manufacturing facilities. Currently it is estimated that there are 60 companies globally within the sector. AT Kearney, a global consultancy, has predicted that Cultivated Meat's market share of meat consumption will be 35% by 2040.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR'). Upon the publication of this announcement via a Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain. 

 

For further information please contact:

 

Agronomics

Limited

Beaumont

Cornish Limited

Cenkos

Securities Plc

Peterhouse Capital

Limited

TB Cardew

The Company

Nomad

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Giles Balleny

Nick Searle

Lucy Williams

Charles Goodfellow

Ed Orlebar

Joe McGregor

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 397 8900

+44 (0) 207 469 0936

+44 (0) 20 7930 0777

+44 (0) 7738 724 630

agronomics@tbcardew.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKNBNQBKDBNB
Date   Source Headline
21st Sep 20227:00 amRNSAgronomics Capital Markets Day 3rd November
8th Sep 20227:00 amRNSPortfolio Update: Bond Pet Foods Completes Funding
7th Sep 20227:00 amRNSPortfolio Company Onego Bio Awarded Grant Funding
11th Aug 20227:00 amRNSEdison issues update on Agronomics (ANIC)
4th Aug 20227:00 amRNSAgronomics Leads All G Foods Series A Financing
1st Aug 20227:00 amRNSAgronomics Leads Clean Food Group’s Seed Financing
25th Jul 20224:40 pmRNSSecond Price Monitoring Extn
25th Jul 20224:35 pmRNSPrice Monitoring Extension
22nd Jul 20227:00 amRNSNet Asset Value calculation to 30 June 2022
20th Jul 20229:03 amRNSPortfolio Company Update: Meatable
18th Jul 202212:24 pmRNSAgronomics July 2022 Newsletter
14th Jul 20227:00 amRNSAppointment of Joint Corporate Broker
8th Jul 202212:29 pmRNSInvestee Company Update: Tropic Biosciences
5th Jul 20227:00 amRNSExercise of Warrants and Total Voting Rights
20th Jun 20227:00 amRNSFinancing of Liberation Labs with CPT Capital
16th May 20229:52 amRNSHolding(s) in Company
6th May 20227:00 amRNSAgronomics Follow-on Investment in CellX
4th May 20229:00 amRNSPortfolio Company VitroLabs completes financing
25th Apr 20227:00 amRNSIssue of Performance Shares & Directors' Dealings
22nd Apr 20227:00 amRNSNet Asset Value calculation to 31st March 2022
5th Apr 20221:25 pmRNSExercise of Warrants, Total Voting Rights
23rd Mar 20229:30 amRNSAnnounces the Trading Facility of Warrants
21st Mar 20228:00 amRNSLaunch of Cultivated Meat Pet Food Venture
18th Mar 20227:00 amRNSANIC Joins the Alternative Proteins Association
14th Mar 20227:00 amRNSAgronomics Follow on Investment in GALY CO.
8th Mar 20227:00 amRNSAgronomics co-leads SuperMeat’s Series A Financing
24th Feb 20227:00 amRNSAgronomics welcomes Senior Investment Associate
22nd Feb 20227:00 amRNSAgronomics Leads Onego Bio's Seed Funding Round
21st Feb 20228:33 amRNSAgronomics Acquires Stake in Geltor, Inc
3rd Feb 20227:00 amRNSInterim Results
2nd Feb 202212:17 pmRNSResult of AGM
27th Jan 20228:00 amRNSPortfolio Company Update: BlueNalu
10th Jan 20228:12 amRNSExercise of Warrants
24th Dec 202111:51 amRNSHolding(s) in Company
23rd Dec 20211:11 pmRNSHolding(s) in Company
23rd Dec 202110:53 amRNSAgronomics December 2021 Newsletter
21st Dec 20212:29 pmRNSOpen Offer Results Subscription PDMR Dealing & TVR
16th Dec 20217:00 amRNSFinal Results and Notice of AGM
10th Dec 202111:08 amRNSHolding(s) in Company
8th Dec 20218:30 amRNSPortfolio Company Update: The EVERY Company
2nd Dec 20211:30 pmRNSResults of the Placing and Subscription
1st Dec 202111:30 amRNSProposed Fundraise to raise minimum £25 million
19th Nov 20217:00 amRNSAgronomics Leads Ohayo Valley’s Pre-Seed Funding
11th Nov 20217:00 amRNSPortfolio Company Update: Tropic Biosciences
5th Nov 20217:00 amRNSNet Asset Value calculation to 30 September 2021
4th Nov 20217:00 amRNSUS$ 8 million investment in The EVERY Company
3rd Nov 20217:00 amRNSAnnounces Launch of New Website
26th Oct 20217:00 amRNSAgronomics EUR3 million investment in Solar Foods
26th Oct 20217:00 amRNSInSilico Medicine sale-Correction of sale proceeds
20th Oct 20218:00 amRNSAgronomics leads investment in California Cultured

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.